Full length articleToxicology studies of PRIMYCIN (cas 113441-12-6)-sulphate using a three-dimensional (3D) in vitro human liver aggregate model
-
Add time:08/12/2019 Source:sciencedirect.com
Primycin-sulphate is a highly effective compound against Gram (G) positive bacteria. It has a potentially synergistic effect with vancomycin and statins which makes primycin-sulphate a potentially very effective preparation. Primycin-sulphate is currently used exclusively in topical preparations. In vitro animal hepatocyte and neuromuscular junction studies (in mice, rats, snakes, frogs) as well as in in vitro human red blood cell experiments were used to test toxicity. During these studies, the use of primycin-sulphate resulted in reduced cellular membrane integrity and modified ion channel activity. Additionally, parenteral administration of primycin-sulphate to mice, dogs, cats, rabbits and guinea pigs indicated high level of acute toxicity.The objective of this study was to reveal the cytotoxic and gene expression modifying effects of primycin-sulphate in a human system using an in vitro, three dimensional (3D) human hepatic model system.Within the 3D model, primycin-sulphate presented no acute cytotoxicity at concentrations 1 μg/ml and below. However, even at low concentrations, primycin-sulphate affected gene expressions by up-regulating inflammatory cytokines (e.g., IL6), chemokines (e.g., CXCL5) and by down-regulating molecules of the lipid metabolism (e.g., peroxisome proliferator receptor (PPAR) alpha, gamma, etc). Down-regulation of PPAR alpha cannot just disrupt lipid production but can also affect cytochrome P450 metabolic enzyme (CYP) 3A4 expression, highlighting the need for extensive drug–drug interaction (DDI) studies before human oral or parenteral preparations can be developed.
We also recommend Trading Suppliers and Manufacturers of PRIMYCIN (cas 113441-12-6). Pls Click Website Link as below: cas 113441-12-6 suppliers
Prev:Synthesis of analogues of Calicheamicin (cas 113440-58-7) and neocarzinostatin chromophore
Next:Re-evaluation of in vitro activity of PRIMYCIN (cas 113441-12-6) against prevalent multiresistant bacteria) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Inhibition of growth of Euglena and Astasia by PRIMYCIN (cas 113441-12-6) and prevention of the effect by polynucleotides08/20/2019
- Preparation of the homologous components (A1, A2 And B) of PRIMYCIN (cas 113441-12-6) by thin-layer chromatography08/19/2019
- The effect of PRIMYCIN (cas 113441-12-6) on the intracellular monovalent ion and water contents of rat hepatocytes as revealed by energy dispersive X-ray microanalysis and interference microscopy08/18/2019
- Effects of PRIMYCIN (cas 113441-12-6) on the synthesis of tryptophan pyrrolase08/17/2019
- PRIMYCIN (cas 113441-12-6) II. New macrocyclic lactones via translactonization08/16/2019
- The composition of PRIMYCIN (cas 113441-12-6)☆08/15/2019
- Direct in vivo interaction of the antibiotic PRIMYCIN (cas 113441-12-6) with the plasma membrane of Candida albicans: An EPR study08/14/2019
- Re-evaluation of in vitro activity of PRIMYCIN (cas 113441-12-6) against prevalent multiresistant bacteria08/13/2019


